Now Reading: Aragen Life Sciences opens high-potency facility in Hyderabad
-
01
Aragen Life Sciences opens high-potency facility in Hyderabad
Contract research, development and manufacturing organisation Aragen Life Sciences has started operations at Aragen OneHP, an integrated high-potency development and manufacturing platform at its Nacharam campus in Hyderabad, the company announced on 7 October.
The 15,000-square-foot facility has one manufacturing line with a designed capacity of 500 to 600 kg of active pharmaceutical ingredients annually. It can handle highly potent compounds, including cytotoxic molecules used in oncology, and is designed for occupational exposure limits of up to 10 ng/m³. The platform will support future expansion into antibody-drug conjugates and peptide-drug conjugates.
Aragen has invested over Rs 1,000 crore in capital expenditure over the three years to March 2026. Its contract development and manufacturing segment registered a 19% compound annual growth rate during this period, with installed small-molecule capacity reaching 364 KL across Hyderabad and Visakhapatnam. The company, which filed for an IPO in August 2026, employs 4,362 people.
Indian Opinion Analysis
All three outlets report the facility’s dimensions, capacity, investment figures and growth rates identically, reflecting a company press release used as the common source. The Hindu adds the IPO context, noting that Aragen filed its DRHP with SEBI in August 2026 for a Rs 800-crore fresh issue and an OFS of over 2.73 crore shares. The Times of India provides additional operational details, such as batch-size ranges for different stages and the 12% growth rate for contract research. Economic Times omits both the IPO mention and the batch-size breakdown. The differences are limited to editorial choices about which company-supplied facts to include, no outlet introduces independent reporting or a critical framing.
Coverage: 3 sources, 3 neutral
Sources (3): economictimes.indiatimes.com (neutral report), thehindu.com (neutral report), timesofindia.indiatimes.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
